Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B

Natera, Inc.

2025-FY EPS reported -$1.52 revenue$2,306,113,000

Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).
Gross margin 66.9% Q4 2025 vs 62.9% Q4 2024; FY2025 gross margin 64.7%.
Oncology test volumes up 54.7% YoY in Q4 (233,300 tests) and 51.6% for FY2025.
Full-year positive cash inflow of $107.6M; net loss $208.2M ($1.52 per diluted share).
FY2026 guidance: revenue $2.62-2.70B, gross margin ~63-65%, positive cash inflow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.